Plandai Biotechnology, Inc.
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | FY12 | FY11 | |
|---|---|---|---|---|---|
| Revenue | $92,898 | $265,748 | $359,143 | $74,452 | — |
| Operating income | −$8.8M | −$8.0M | −$2.7M | −$3.8M | −$135,951 |
| Net income | −$10.1M | −$16.0M | −$3.0M | −$3.8M | −$84,751 |
| Total assets | $8.5M | $9.7M | $8.8M | $6.1M | $174 |
| Total liabilities | $16.8M | $13.2M | $12.3M | $6.9M | $221,785 |
| Equity | −$6.5M | −$2.2M | −$2.6M | −$882,174 | −$750,197 |
| EPS (diluted) | — | — | — | — | — |
| Shares out. | 164.4M | 134.2M | 106.3M | 110.9M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- −9526.1%
- Net margin
- −10842.4%
- Return on equity
- 155.0%
- Return on assets
- −118.4%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 197.8%
- Debt / equity
- —
- Book value / share
- $-0.04
- Revenue growth (YoY)
- −65.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Altman Z″ (distress)
- -32.68distress
- Accruals / assets
- −86.6%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Sep 28, 2016
- NT 10-Qmissed a reporting deadline ↗Nov 16, 2015
- NT 10-Kmissed a reporting deadline ↗Sep 28, 2015
- NT 10-Qmissed a reporting deadline ↗May 15, 2015
- NT 10-Kmissed a reporting deadline ↗Sep 29, 2014
- NT 10-Qmissed a reporting deadline ↗Feb 14, 2014
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Johnson BrianDirector | Mar 30, 2012 | Grant | 1.5M | $0.23 |
| Rzepnicki DavidDirector | Mar 8, 2012 | Grant | 150,000 | $0.06 |
| Baylis-Duffield CallumDirector | Jan 1, 2014 | Grant | 1.0M | $0.06 |
| Duffield Daron BaylisDirector | Mar 8, 2012 | Grant | 450,000 | $0.32 |
| Duffield RogerOfficer — President, Secretary and CFO | Mar 8, 2012 | Grant | 803,400 | $0.32 |
| Matula Timothy | Feb 7, 2013 | Sell | 4.9M | $0.03 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Amended charter or bylaws · Shareholder vote · Other material eventSep 21, 2016
- Changed auditor · Prior financials not reliable (restatement)Apr 27, 2016
- Director / officer changeMar 2, 2016
- Changed auditorOct 9, 2015
- Changed auditorSep 25, 2015
- Director / officer changeJun 10, 2015
- Changed auditorApr 28, 2015
- Terminated a material agreementSep 9, 2014
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QMar 20, 2023
- 10-KMar 16, 2023
- SC 13G/AAMENDMENT NO. 6 TO SCHEDULE 13GFeb 15, 2022
- SC 13G/AAMENDMENT NO.1 TO SCHEDULE 13GJan 27, 2021
- SC 13GSCHEDULE 13GJan 21, 2021
- SC 13G/AAMENDMENT NO.4 TO SCHEDULE 13GFeb 13, 2020
- SC 13G/AAMENDMENT NO. 3 TO SCHEDULE 13GFeb 15, 2019
- SC 13GFeb 14, 2018
- SC 13G/ASCHEDULE 13G/A2Apr 24, 2017
- SC 13G/AFeb 1, 2017
- 15-12GFORM 15-12GJan 31, 2017
- NT 10-KSep 28, 2016
- SC 13GSep 27, 2016
- 8-KFORM 8-KSep 21, 2016
- SC 13GSCHEDULE 13GSep 1, 2016
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.